Two Year Treatment w/Teriflunomide vs. Placebo for MS

ID Number 08-0364

Principal Investigator(s)
Teresa M. DeAngelis

Department(s) or Division(s)
Neurology

Description
The purpose of this study is to evaluate the effectiveness and the potential risks of teriflunomide at the doses of 7 and 14 mg once daily compared to placebo (substance which contains no active medication) in the treatment of patients presenting with their first neurological episode suggestive of MS and who have abnormalities on a Brain MRI that shows a risk of developing MS.

Contact Information
Christine Hannigan
(212) 241-7858
christine.hannigan


Recruiting Patients: Yes